EXTH-48. NOVEL COMBINATION THERAPY IN PRECLINICAL GLIOMA MODELS USING THE CELL CYCLE STABILIZING COMPOUND ARGYRIN F AND CHECKPOINT INHIBITION. (12th November 2021)

• Record Type: Journal Article
• Authors: Walter, Bianca; Canjuga, Denis; Yuez, Simge G; Ghosh, Michael; Bozko, Przemyslaw; Przystal, Justyna; Govindarajan, Parameswari; Anderle, Nicole; Keller, Anna-Lena; Tatagiba, Marcos; Schenke-Layland, Katja; Rammensee, Hans-Georg; Stevanovic, Stefan; Malek, Nisar P; Schmees, Christian; Tabatabai, Ghazaleh
• Is Part Of: Neuro-oncology. Volume 23: Supplement 6(2021)
• Page Start: vi174
• Page End: vi174
• Publication Date: 2021-11-12
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab196.687
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Glioblastoma are incurable aggressive tumors and remain a therapeutic challenge. Glioblastoma frequently harbor alterations in the retinoblastoma pathway with subsequent cell cycle abnormalities. Here, we aimed to investigate the anti-glioma activity of the cell cycle-stabilizing compound Argyrin F and its potential treatment-induced vulnerabilities to exploit possibilities for novel combination therapies. We investigated cell viability, clonogenic survival, cell cycle status and immunoblots of human and murine glioma cells treated with Argyrin F. Moreover, we established an ex vivo glioma model using residual freshly resected tissue from patients, i.e. patient-derived microtumors (PDMs). Additionally, we extracted autologous tumor infiltrating lymphocytes (TILs) to perform co-culturing experiments. We performed mass spectrometry-based immunopeptidomics and used the orthotopic syngeneic SMA560/VM/Dk glioma mouse model. Argyrin F displayed anti-glioma efficacy in glioma cell lines in vitro and in PDM models ex vivo . Moreover, Argyrin F treatment induced cell cycle arrest, reduced clonogenic survival in vitro and prolonged survival in vivo. Argyrin F-treated SMA560 glioma displayed 4.6-fold more glioma-infiltrating CD8 + T cells. We discovered a distinctive treatment-induced immunopeptidome. Combination of Argyrin F plus PD-1 antibody increased cellular toxicity in PDM/TILs co-cultures ex vivo and prolonged overall survival compared with monotherapies in vivo . We conclude that our experimental data suggest a novel combination of Argyrin F plus PD-1 blockade and its clinical translation.